Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Dow
Johnson and Johnson
Colorcon
Mallinckrodt
Express Scripts

Last Updated: July 1, 2022

CLINICAL TRIALS PROFILE FOR OMNIPAQUE 240


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Omnipaque 240

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00478556 ↗ Omnipaque Versus Gastroview as Oral Contrast for Abdominal and Pelvic CT Completed GE Healthcare Phase 4 2007-08-01 Patients who are scheduled by their health care provider for routine computed tomography (CT) scan will be asked to participate in this study. The primary purpose is to determine if there is a difference in patient preference for Omnipaque versus Gastroview as oral contrast for abdominal pelvic CT. A secondary objective is to evaluate if there is significant difference in bowel opacification for the two agents.
NCT00478556 ↗ Omnipaque Versus Gastroview as Oral Contrast for Abdominal and Pelvic CT Completed University of Alabama at Birmingham Phase 4 2007-08-01 Patients who are scheduled by their health care provider for routine computed tomography (CT) scan will be asked to participate in this study. The primary purpose is to determine if there is a difference in patient preference for Omnipaque versus Gastroview as oral contrast for abdominal pelvic CT. A secondary objective is to evaluate if there is significant difference in bowel opacification for the two agents.
NCT00587132 ↗ Secretin (ChiRhoStim) Pancreas Perfusion for Pancreatic Adenocarcinoma Terminated ChiRhoClin, Inc. Phase 1/Phase 2 2006-11-01 The purpose of this study is to test if secretin-enhanced CT is a useful noninvasive screening tool for pancreatic cancer in a high-risk population.
NCT00587132 ↗ Secretin (ChiRhoStim) Pancreas Perfusion for Pancreatic Adenocarcinoma Terminated Mayo Clinic Phase 1/Phase 2 2006-11-01 The purpose of this study is to test if secretin-enhanced CT is a useful noninvasive screening tool for pancreatic cancer in a high-risk population.
NCT00857792 ↗ Multivariable Assessment of Coronary Artery Disease Using Cardiac CT Imaging Completed Astellas Pharma Inc N/A 2009-03-01 The investigators goals are: 1. to develop software for quantitative volumetric analysis of myocardial perfusion from MDCT images 2. to test its ability to accurately determine the presence, location, extend and severity of perfusion abnormalities in agreement with conventional diagnostic techniques (ICA and MPI) in patients with normal and abnormal coronary arteries and/or perfusion patterns 3. to test this approach in patients undergoing vasodilator stress tests with MDCT imaging in combination with the new vasodilator stress agent Regadenoson.
NCT00857792 ↗ Multivariable Assessment of Coronary Artery Disease Using Cardiac CT Imaging Completed University of Chicago N/A 2009-03-01 The investigators goals are: 1. to develop software for quantitative volumetric analysis of myocardial perfusion from MDCT images 2. to test its ability to accurately determine the presence, location, extend and severity of perfusion abnormalities in agreement with conventional diagnostic techniques (ICA and MPI) in patients with normal and abnormal coronary arteries and/or perfusion patterns 3. to test this approach in patients undergoing vasodilator stress tests with MDCT imaging in combination with the new vasodilator stress agent Regadenoson.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Omnipaque 240

Condition Name

Condition Name for Omnipaque 240
Intervention Trials
Malignant Solid Neoplasm 1
Chronic Kidney Disease 1
HIV 1
Mesothelioma 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Omnipaque 240
Intervention Trials
Coronary Artery Disease 3
Myocardial Ischemia 2
Heart Diseases 1
Aortic Aneurysm 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Omnipaque 240

Trials by Country

Trials by Country for Omnipaque 240
Location Trials
United States 47
France 2
Colombia 1
Puerto Rico 1
Korea, Republic of 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Omnipaque 240
Location Trials
Pennsylvania 3
Minnesota 3
California 3
Ohio 2
Maryland 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Omnipaque 240

Clinical Trial Phase

Clinical Trial Phase for Omnipaque 240
Clinical Trial Phase Trials
Phase 4 5
Phase 3 1
Phase 2 1
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Omnipaque 240
Clinical Trial Phase Trials
Completed 8
Recruiting 7
Not yet recruiting 3
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Omnipaque 240

Sponsor Name

Sponsor Name for Omnipaque 240
Sponsor Trials
GE Healthcare 2
National Cancer Institute (NCI) 2
Tufts Medical Center 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Omnipaque 240
Sponsor Trials
Other 22
Industry 12
NIH 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
Medtronic
Merck
Express Scripts
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.